tetano
Editor, Senior Moderator
Sci Rep
. 2024 Jul 9;14(1):15864.
doi: 10.1038/s41598-024-66558-0. Selection and characterization of human scFvs targeting the SARS-CoV-2 nucleocapsid protein isolated from antibody libraries of COVID-19 patients
Simonetta Lisi[SUP] #[/SUP][SUP] 1 [/SUP], Francesca Malerba[SUP] #[/SUP][SUP] 2 [/SUP], Paola Quaranta[SUP] 3 4 [/SUP], Rita Florio[SUP] 2 [/SUP], Ottavia Vitaloni[SUP] 1 [/SUP], Elisa Monaca[SUP] 5 [/SUP], Bruno Bruni Ercole[SUP] 2 [/SUP], Angela Rachel Bitonti[SUP] 1 [/SUP], Olga Del Perugia[SUP] 1 [/SUP], Marianna Mignanelli[SUP] 1 [/SUP], Paola Perrera[SUP] 3 [/SUP], Raffaele Sabbatella[SUP] 5 [/SUP], Francesco Raimondi[SUP] 1 [/SUP], Carmen Rita Piazza[SUP] 3 6 [/SUP], Anna Moles[SUP] 7 8 [/SUP], Caterina Alfano[SUP] 5 [/SUP], Mauro Pistello[SUP] 3 4 [/SUP], Antonino Cattaneo[SUP] 9 10 [/SUP]
Affiliations
In 2019, the novel SARS-CoV-2 coronavirus emerged in China, causing the pneumonia named COVID-19. At the beginning, all research efforts were focused on the spike (S) glycoprotein. However, it became evident that the nucleocapsid (N) protein is pivotal in viral replication, genome packaging and evasion of the immune system, is highly immunogenic, which makes it another compelling target for antibody development alongside the spike protein. This study focused on the construction of single chain fragments variable (scFvs) libraries from SARS-CoV-2-infected patients to establish a valuable, immortalized and extensive antibodies source. We used the Intracellular Antibody Capture Technology to select a panel of scFvs against the SARS-CoV-2 N protein. The whole panel of scFv was expressed and characterized both as intrabodies and recombinant proteins. ScFvs were then divided into 2 subgroups: those that exhibited high binding activity to N protein when expressed in yeast or in mammalian cells as intrabodies, and those purified as recombinant proteins, displaying affinity for recombinant N protein in the nanomolar range. This panel of scFvs against the N protein represents a novel platform for research and potential diagnostic applications.
. 2024 Jul 9;14(1):15864.
doi: 10.1038/s41598-024-66558-0. Selection and characterization of human scFvs targeting the SARS-CoV-2 nucleocapsid protein isolated from antibody libraries of COVID-19 patients
Simonetta Lisi[SUP] #[/SUP][SUP] 1 [/SUP], Francesca Malerba[SUP] #[/SUP][SUP] 2 [/SUP], Paola Quaranta[SUP] 3 4 [/SUP], Rita Florio[SUP] 2 [/SUP], Ottavia Vitaloni[SUP] 1 [/SUP], Elisa Monaca[SUP] 5 [/SUP], Bruno Bruni Ercole[SUP] 2 [/SUP], Angela Rachel Bitonti[SUP] 1 [/SUP], Olga Del Perugia[SUP] 1 [/SUP], Marianna Mignanelli[SUP] 1 [/SUP], Paola Perrera[SUP] 3 [/SUP], Raffaele Sabbatella[SUP] 5 [/SUP], Francesco Raimondi[SUP] 1 [/SUP], Carmen Rita Piazza[SUP] 3 6 [/SUP], Anna Moles[SUP] 7 8 [/SUP], Caterina Alfano[SUP] 5 [/SUP], Mauro Pistello[SUP] 3 4 [/SUP], Antonino Cattaneo[SUP] 9 10 [/SUP]
Affiliations
- PMID: 38982108
- PMCID: PMC11233501
- DOI: 10.1038/s41598-024-66558-0
In 2019, the novel SARS-CoV-2 coronavirus emerged in China, causing the pneumonia named COVID-19. At the beginning, all research efforts were focused on the spike (S) glycoprotein. However, it became evident that the nucleocapsid (N) protein is pivotal in viral replication, genome packaging and evasion of the immune system, is highly immunogenic, which makes it another compelling target for antibody development alongside the spike protein. This study focused on the construction of single chain fragments variable (scFvs) libraries from SARS-CoV-2-infected patients to establish a valuable, immortalized and extensive antibodies source. We used the Intracellular Antibody Capture Technology to select a panel of scFvs against the SARS-CoV-2 N protein. The whole panel of scFv was expressed and characterized both as intrabodies and recombinant proteins. ScFvs were then divided into 2 subgroups: those that exhibited high binding activity to N protein when expressed in yeast or in mammalian cells as intrabodies, and those purified as recombinant proteins, displaying affinity for recombinant N protein in the nanomolar range. This panel of scFvs against the N protein represents a novel platform for research and potential diagnostic applications.